OTCMKTS:AFFY

Affymax - AFFY Stock Forecast, Price & News

$0.0062

0.00 (0.00%)

(As of 08/11/2022 12:00 AM ET)

Add

Compare

Today's Range: $0.01
▼
$0.01
50-Day Range: $0.01
▼
$0.01
52-Week Range: $0.00
▼
$0.05

Volume: N/A
Average Volume: 5,042 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About Affymax (OTCMKTS:AFFY) Stock

Affymax, Inc. does not have significant operations. Previously, it was developing drugs to enhance the treatment of serious and often life-threatening conditions in the United States. The company was founded in 2001 and is based in New York, New York.

Receive AFFY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Affymax and its competitors with MarketBeat's FREE daily newsletter.

AFFY Stock News Headlines

August 3, 2022 | investing.com

Esso Thailand PCL F (ESSOf)

August 3, 2022 | investing.com

Dialog Group Bhd (DIAL)

July 30, 2022 | investing.com

DPS Resources Bhd (DPSS)

April 27, 2022 | marketwatch.com

Renal Disease Treatment Market Size with New Growth Prospect By Top Key Players | Impact of COVID-19 Pandemic

March 27, 2022 | marketwatch.com

Renal Disease Treatment Market Scope with New Growth Prospect By Top Key Players | Impact of COVID-19 Pandemic

September 2, 2021 | ca.finance.yahoo.com

Arcutis Announces Appointment of Keith Leonard to Board of Directors

April 28, 2021 | ca.finance.yahoo.com

Dr. Mike Holfinger Joins Alladapt as Chief Technical Officer

December 29, 2020 | marketwatch.com

PEGylated Protein Therapeutics Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast 2020 to 2027

August 16, 2020 | markets.businessinsider.com

Affymax IncShs - Profile

July 23, 2020 | www.marketwatch.com

Affymax Inc.

March 8, 2020 | www.bloomberg.com

Pomerantz Law Firm Announces Summary Notice of Pendency and Proposed Settlement of Affymax, Inc. Class Action and Settlement

December 4, 2019 | finance.yahoo.com

RubrYc Therapeutics Announces formation of its Scientific Advisory Board

July 11, 2019 | www.marketwatch.com

Atreca Further Strengthens Management Team with Appointment of Lisa Decker as Chief Business Officer and Courtney Phillips as General Counsel

December 31, 2018 | www.bizjournals.com

Health Care Digest: Why another event is joining the JPM crowd, IPO ties that bind and more

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive AFFY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Affymax and its competitors with MarketBeat's FREE daily newsletter.

AFFY Company Calendar

Today: 8/11/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: OTCMKTS:AFFY
CUSIP: 00826A10
CIK: 1158223
Web: www.affymax.com
Phone: (650) 812-8700
Fax: 650-424-0832
Employees: 2
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: 5.98

Key Executives

Mr. Mark G. Thompson (Age 60)
CFO & Sec.
Comp: $97.49k
Mr. Jonathan M. Couchman (Age 52)
CEO, Pres & Director
Dr. Tracy J. Dunn Ph.D. (Age 59)
J.D., VP of Intellectual Property & Legal Affairs

Key Competitors

View All Competitors

AFFY Stock - Frequently Asked Questions

How have AFFY shares performed in 2022?: Affymax's stock was trading at $0.0060 at the beginning of 2022. Since then, AFFY shares have increased by 3.3% and is now trading at $0.0062.
View the best growth stocks for 2022 here.
What other stocks do shareholders of Affymax own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Affymax investors own include Golden Peak Minerals Inc.. (GRM), (MCPIQ) (MCPIQ), Bank of America (BAC), Boeing (BA), American Express (AXP), Aurinia Pharmaceuticals (AUPH), Actinium Pharmaceuticals (ATNM), Advanced Micro Devices (AMD), Alnylam Pharmaceuticals (ALNY) and Achaogen (AKAO).

What is Affymax's stock symbol?: Affymax trades on the OTCMKTS under the ticker symbol "AFFY."
How do I buy shares of Affymax?: Shares of AFFY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Affymax's stock price today?: One share of AFFY stock can currently be purchased for approximately $0.01.
How can I contact Affymax?: Affymax's mailing address is 19200 STEVENS CREEK BOULEVARD SUITE 240, CUPERTINO CA, 95014. The official website for the company is www.affymax.com. The biopharmaceutical company can be reached via phone at (650) 812-8700, via email at investors@affymax.com, or via fax at 650-424-0832.

This page (OTCMKTS:AFFY) was last updated on 8/11/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

MarketBeat Resources